Literature DB >> 15796961

Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes.

Susana Mendoza1, Heldi David, Grace M Gaylord, Carl W Miller.   

Abstract

Loss of heterozygosity at 10q26 was mapped using microsatellite markers in 20 osteosarcomas. A four-megabase region centered on marker D10S587 was affected by allelic loss in 60 percent of osteosarcomas. The most frequently lost marker was D10S1723. Around 15 known genes are found in this region. The gene immediately adjacent to D10S1723 encodes BUB3, an element of the spindle assembly mitotic checkpoint. Loss of BUB3 function could contribute to chromosomal instability. The fibroblast growth factor receptor 2 (FGFR2) gene is located 2 Mb from the BUB3 gene and has the potential for a role in cancer. Inherited mutations of the FGFR2 gene result in skeletal dysplasias. FGFR2 alterations have also been implicated in gastric cancer. Human genome project data were used to design primers for amplifying FGFR2 in 18 genomic segments and BUB3 in 7 genomic segments. In each case, the segments encompassed coding exons and flanking intron sequences. The primers were used to search for mutations by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). Several shifted bands were detected in the BUB3 exon 3 fragment. Sequencing resolved the BUB3 exon 3 fragment shifts into polymorphisms in intron 2. No mutations of BUB3 or FGFR2 were detected. It remains possible that BUB3 or FGFR2 hemizygosity alone contributes to osteosarcoma, or that one of the genes is cryptically inactivated by a higher-order modification or mutation outside the coding region. There may also be a yet undiscovered tumor suppressor gene in this region.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15796961     DOI: 10.1016/j.cancergencyto.2004.08.035

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  18 in total

1.  Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Authors:  Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer
Journal:  Int Orthop       Date:  2010-03-26       Impact factor: 3.075

2.  Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer.

Authors:  Xuegong Zhu; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

3.  Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese.

Authors:  Shusuke Akamatsu; Ryo Takata; Christopher A Haiman; Atsushi Takahashi; Takahiro Inoue; Michiaki Kubo; Mutsuo Furihata; Naoyuki Kamatani; Johji Inazawa; Gary K Chen; Loïc Le Marchand; Laurence N Kolonel; Takahiko Katoh; Yuko Yamano; Minoru Yamakado; Hiroyuki Takahashi; Hiroki Yamada; Shin Egawa; Tomoaki Fujioka; Brian E Henderson; Tomonori Habuchi; Osamu Ogawa; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Nat Genet       Date:  2012-02-26       Impact factor: 38.330

Review 4.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

5.  Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer.

Authors:  Xuegong Zhu; Sylvia L Asa; Shereen Ezzat
Journal:  Mol Endocrinol       Date:  2009-06-04

Review 6.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

7.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

8.  Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Authors:  Natacha Entz-Werle; Thomas Lavaux; Nadia Metzger; Corinne Stoetzel; Christelle Lasthaus; Perrine Marec; Chantal Kalifa; Laurence Brugieres; Hélène Pacquement; Claudine Schmitt; Marie-Dominique Tabone; Jean-Claude Gentet; Patrick Lutz; Annie Babin; Pierre Oudet; Marie Pierre Gaub; Fabienne Perrin-Schmitt
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

9.  Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas.

Authors:  Michalis Liontos; Katerina Niforou; Georgia Velimezi; Konstantinos Vougas; Konstantinos Evangelou; Kalliopi Apostolopoulou; Radek Vrtel; Alexandros Damalas; Panayiotis Kontovazenitis; Athanassios Kotsinas; Vassilis Zoumpourlis; George Th Tsangaris; Christos Kittas; Doron Ginsberg; Thanos D Halazonetis; Jiri Bartek; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

Review 10.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.